Global Blood Therapeutics (GBT) Getting Somewhat Positive Press Coverage, Analysis Finds

Global Blood Therapeutics (GBT) Getting Somewhat Positive Press Coverage, Analysis Finds

Press coverage about Global Blood Therapeutics (NASDAQ:GBT) has been trending somewhat positive recently, according to Alpha One Sentiment Analysis. The research firm, a division of Accern, ranks the sentiment of press coverage by analyzing more than 20 million blog and news sources in real time. Alpha One ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Global Blood Therapeutics earned a daily sentiment score of 0.22 on Alpha One’s scale. Alpha One also gave headlines about the company an impact score of 0 out of 100, indicating that recent press coverage is extremely unlikely to have an impact on the stock’s share price in the next several days.

Here are some of the news headlines that may have effected Alpha One Sentiment Analysis’s rankings:

A number of research analysts have commented on the stock. Wedbush reiterated an “outperform” rating and set a $73.00 price objective on shares of Global Blood Therapeutics in a research note on Tuesday, May 2nd. Janney Montgomery Scott initiated coverage on shares of Global Blood Therapeutics in a research report on Monday, May 1st. They issued a “buy” rating and a $37.00 price target on the stock. SunTrust Banks, Inc. initiated coverage on shares of Global Blood Therapeutics in a research report on Monday, April 17th. They issued a “buy” rating and a $56.00 price target on the stock. Roth Capital set a $47.00 price target on shares of Global Blood Therapeutics and gave the stock a “buy” rating in a research report on Monday, March 20th. Finally, Zacks Investment Research downgraded shares of Global Blood Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, March 16th. One analyst has rated the stock with a sell rating and eleven have issued a buy rating to the company. Global Blood Therapeutics presently has an average rating of “Buy” and a consensus price target of $50.37.

Global Blood Therapeutics (NASDAQ GBT) traded down 2.048% on Thursday, hitting $26.447. 259,489 shares of the stock were exchanged. The stock’s market cap is $1.15 billion. The company’s 50 day moving average is $29.76 and its 200 day moving average is $24.76. Global Blood Therapeutics has a 1-year low of $13.35 and a 1-year high of $41.15.

Global Blood Therapeutics (NASDAQ:GBT) last posted its quarterly earnings results on Monday, May 1st. The company reported ($0.60) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.71) by $0.11. During the same quarter last year, the company posted ($0.56) EPS. On average, equities research analysts expect that Global Blood Therapeutics will post ($2.55) earnings per share for the current year.

In other Global Blood Therapeutics news, major shareholder Robert I. Tepper sold 31,225 shares of Global Blood Therapeutics stock in a transaction on Thursday, April 6th. The shares were sold at an average price of $33.23, for a total transaction of $1,037,606.75. Following the sale, the insider now owns 229,773 shares in the company, valued at $7,635,356.79. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 6.10% of the stock is owned by insiders.

Global Blood Therapeutics Company Profile

Global Blood Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD).new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:GBT”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Related posts

Leave a Comment